I'm with the Bulls, Long BMY | BMY Message Board Posts

Bristol-Myers Squibb Co.

  BMY website

BMY   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  5165 of 5859  at  11/27/2020 10:08:59 AM  by

billmax


I'm with the Bulls, Long BMY

Bulls Say:
Bristol's growth prospects are focused on new cancer indications for Opdivo and cardiovascular drug Eliquis, which holds leading efficacy data within the atrial fibrillation class.
The oncology drug Opdivo holds the potential to radically shift the treatment paradigm in several cancer indications, which should result in peak sales of more than $10 billion annually.
More than half of Bristol's late-stage pipeline focuses on immunology and cancer--indications, where the FDA aggressively approves drugs and which typically hold strong pricing power.
Bears Say:
The acquisition of Celgene brings generic competition for cancer drug Revlimid in 2022, setting up a major growth obstacle.
We believe a large portion of Bristol's valuation is tied to cancer drug Opdivo, which could have an amplified negative impact on the stock if clinical data are poor or if competitors report superior data to Opdivo.
Bristol’s recent move to acquire Celgene adds significant debt that could become challenging to repay if competition strengthens against key drugs or pricing pressures increase in the U.S.
Morningstar Equity Analyst Report  


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 0
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board








Financial Market Data provided by
.
Loading...